Gabapentin
Product Images NDC 68071-3498

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-3498). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3498 1)

Gabapentin 100 mg capsules label from NuCare Pharmaceuticals, Inc. The label includes the NDC 68071-3498, product number R1132100, and packaging details for 100 capsules. It notes the product is Rx only, with manufacturer details for Zhejiang Yongtai Pharmaceutical Co., Ltd., China. Storage and safety warnings are printed along with lot, expiration, and serial numbers.*

FDA Label Image

Image Description (Gabapentincapsules 01)

An illustration showing the Cockcroft-Gault equation formula for estimating creatinine clearance (CLCr). The formula calculates CLCr based on age (years), weight (kg), and serum creatinine (mg/dL), with an adjustment factor of 0.85 for female patients. The image is related to the pharmacokinetics of Gabapentin by NuCare Pharmaceuticals, Inc.*

FDA Label Image

Chemical Structure (Gabapentincapsules 02)

Chemical structure of gabapentin showing a cyclohexane ring bonded to an amino group (CH2NH2) and a carboxymethyl group (CH2CO2H). The diagram illustrates the molecular arrangement of the active ingredient gabapentin.*

FDA Label Image

Figure 1 (Gabapentincapsules 03)

A line graph showing mean pain scores over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Gabapentin scores decrease steadily over time while placebo scores remain relatively stable.*

FDA Label Image

Figure 2 (Gabapentincapsules 04)

A line graph showing the mean pain score over a 7-week period comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The timeline includes a 3-week dose titration period followed by a 4-week fixed-dose period. The graph illustrates a decrease in pain scores for both gabapentin doses compared to placebo over time.*

FDA Label Image

Figure 3 (Gabapentincapsules 05)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies,' comparing placebo (PBO) and Gabapentin (GBP) at different dosages in two studies. Study 1 shows 12% responders with placebo and 29% with Gabapentin 3600 mg. Study 2 shows 14% responders with placebo, 32% with Gabapentin 1800 mg, and 34% with Gabapentin 2400 mg. Statistical significance is indicated by p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4 (Gabapentincapsules 06)

A scatter plot comparing the percentage difference by daily dose (mg) for Gabapentin across three studies labeled as STUDY a, STUDY b, and STUDY c. The x-axis shows daily doses from 600 mg to 1800 mg, and the y-axis shows difference percentages from 2% to 22%. Points are marked with different symbols and letters for each study.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.